Kehoe Law Firm Investigates Ionis Pharmaceuticals Following Sales Guidance Cut

Kehoe Law Firm announced an investigation into Ionis Pharmaceuticals on behalf of investors after the company cut its 2026 sales forecast for TRYNGOLZA on November 9, 2026. The investigation will examine whether Ionis adequately disclosed adverse sales trends and commercialization challenges known to management during the third quarter. The firm is inviting investors who incurred losses to contact it for an evaluation of potential legal claims.